Cas:898561-65-4 N-(5-hydroxypyridin-2-yl)-2,2-dimethylpropanamide manufacturer & supplier

Chemical Name:N-(5-hydroxypyridin-2-yl)-2,2-dimethylpropanamide

CAS.NO:898561-65-4

Synonyms:N-(5-hydroxypyridin-2-yl)-2,2-dimethylpropanamide

Molecular Formula:C₁₀H₁₄N₂O₂

Molecular Weight:194.23000

HS Code:2933399090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:488.6ºC at 760 mmHg

Density:1.186g/cm3

Index of Refraction:1.578

PSA:62.22000

Exact Mass:194.10600

LogP:1.84480

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like N-(5-hydroxypyridin-2-yl)-2,2-dimethylpropanamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-(5-hydroxypyridin-2-yl)-2,2-dimethylpropanamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-(5-hydroxypyridin-2-yl)-2,2-dimethylpropanamide Use and application,N-(5-hydroxypyridin-2-yl)-2,2-dimethylpropanamide technical grade,usp/ep/jp grade.

Related News: In addition, a high-standard GMP workshop is under construction and is expected to be put into production within the year. As the capacity bottleneck is broken, the pharmaceutical intermediate business is expected to grow rapidly in the future, providing the company with new growth momentum. N-(5-hydroxypyridin-2-yl)-2,2-dimethylpropanamide manufacturer Lilly did show much more conclusively that donanemab, which zeroes in on amyloid plaques, does reduce levels of the aggregates of misfolded proteins in the brain. This is what Biogen also showed with Aduhelm, and it turned out this week to be enough for a full FDA approval, hence the stock bump for Lilly. N-(5-hydroxypyridin-2-yl)-2,2-dimethylpropanamide supplier A key publication in a preclinical model demonstrated rigosertib��s ability to block cellular signaling by targeting RAS effector pathways (Divakar, S.K., et al., 2016: ��A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.�� Cell 165, 643). N-(5-hydroxypyridin-2-yl)-2,2-dimethylpropanamide vendor In addition, a high-standard GMP workshop is under construction and is expected to be put into production within the year. As the capacity bottleneck is broken, the pharmaceutical intermediate business is expected to grow rapidly in the future, providing the company with new growth momentum. N-(5-hydroxypyridin-2-yl)-2,2-dimethylpropanamide factory Lilly did show much more conclusively that donanemab, which zeroes in on amyloid plaques, does reduce levels of the aggregates of misfolded proteins in the brain. This is what Biogen also showed with Aduhelm, and it turned out this week to be enough for a full FDA approval, hence the stock bump for Lilly.